Described herein are methods, compositions, and systems useful for detecting transplant rejection and associated abnormal conditions in liver transplant recipients involving an assessment of donor-derived cell-free nucleic acids (dd-cfNA) such as donor-derived cell-free DNA (dd-cfDNA).
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
Provided herein are self-assembling peptide amphiphiles (PAs) comprising a bioactive Transforming growth factor beta 1 (TGF-?1) mimetic epitope, high-aspect-ratio nanostructures of PAs displaying a TGF-?1 mimetic epitope, and methods of enhancing cartilage regeneration/repair and/or treatment of osteoarthritis and other musculoskeletal injuries and diseases.
Described herein are methods, compositions, and systems useful for detecting transplant rejection and associated abnormal conditions in solid organ transplant recipients, such as kidney transplant recipients. Methods described herein may involve combined assessment of blood gene expression profiles from an assessment of particular, related mRNA transcript levels and donor-derived cell-free nucleic acids (dd-cfDNA).
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
Provided is a process for hydrogenolysis of a polymer that includes providing in a reactor the polymer, hydrogen gas and a supported organometallic catalyst. The supported organometallic catalyst formed from an organometallic complex precatalyst and an acidic metal oxide support. The polymer is reacted with the supported organometallic catalyst in the presence of the hydrogen gas at a predetermined temperature in the reactor to produce a reduced polymer product having a weight average molecular weight less than the polymer.
Provided herein are compositions and methods for the inhibition of nerve growth factor (NGF) and the treatment/prevention of atrial fibrillation. In particular, inhibitors of NGF expression are administered to the myocardial tissue of a subject to treat or prevent atrial fibrillation and/or autonomic nerve sprouting in the atria.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
6.
ANALYTE DETECTION CARTRIDGE AND METHODS OF USE THEREOF
Provided herein are devices (e.g., cartridges), instruments, systems, and components thereof for rapid sample processing and analyte detection (e.g., nucleic acid purification, amplification, and/or detection), and methods of use thereof. A cartridge for analyte detection may comprise: a storage section including a storage chamber; a processing section including a processing chamber; a microfluids section in fluid communication with the processing section; and a transfer capsule configured to transfer fluid between the storage chamber and the processing chamber
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
C12N 1/00 - Micro-organismes, p.ex. protozoaires; Compositions les contenant; Procédés de culture ou de conservation de micro-organismes, ou de compositions les contenant; Procédés de préparation ou d'isolement d'une composition contenant un micro-organisme; Leurs milieux de culture
C12N 3/00 - Procédés pour former ou isoler des spores
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
7.
INHIBITORS OF UBIQUITIN SPECIFIC PEPTIDASE 22 (USP22) AND USES THEREOF FOR TREATING DISEASES AND DISORDERS
Disclosed are methods of treating diseases or disorders associated with the expression of Ubiquitin Specific Peptidase 22 (USP22). The disclosed methods may be utilized to treat diseases or disorders associated with cell proliferation, including cancer. Also disclosed are inhibitors of USP22 that specifically inhibit the EC:3.4.19.12 activity, or the thiol-dependent hydrolysis of ester, thioester, amide, peptide and isopeptide bonds formed by the C-terminal glycine of ubiquitin. The disclosed compounds may also be used in pharmaceutical compositions and methods for treatment of cell proliferative diseases or disorders associated with USP22 activity.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
8.
BENCHTOP INSTRUMENT AND CONSUMABLES FOR SAMPLE DEPOSITION AND STAINING
An apparatus for depositing and staining a cellular sample, includes a slide processing module comprising a specimen input port (SIP) dock configured to receive a SIP consumable comprising the cellular sample, and position the SIP consumable such that a spray nozzle of the SIP consumable and an air nozzle of the slide processing module are aligned prior to a deposition operation, and a user interface configured receive an input from a user that configures the deposition operation and a staining operation, and an auxiliary systems module, coupled to the slide processing module, comprising a chassis including a removable storage container configured to hold a plurality of bottles comprising one or more of a reagent, a buffer solution, or an ethanol-based fixative, and an electronics subsystem configured to execute, based on the input from the user, a pre-programmed protocol for the deposition operation and the staining operation.
The disclosure is generally related to spherical nucleic acids (SNAs), nanostructures with a core surrounded by a radial presentation of oligonucleotides, that can target multiple classes of immune cells. Methods of making and using the nanoparticles are also provided herein. In some aspects, the disclosure provides a spherical nucleic acid (SNA) comprising: (a) a nanoparticle core; (b) a shell of oligonucleotides attached to the external surface of the nanoparticle core, the shell of oligonucleotides comprising one or more immunostimulatory oligonucleotides; and (c) a first antigen that is a major histocompatibility complex type I (MHC-I) antigen, and a second antigen that is a major histocompatibility complex type II (MHC-I I) antigen.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
The present invention provides nanocarriers for delivering polynucleotide sequences to cells, specifically immune cells, including dendritic cells and methods of use. The methods provide improved delivery and reduced toxicity over prior methods. The method of the present disclosure provide a system for delivering nucleic acids to a cell, consisting of a synthetic PEG-b-PPS-linker-DP polymer for producing nanostructures comprising a poly(ethylene glycol)-blockpoly(propylene sulfide) copolymer (PEG-b-PPS) conjugated with a dendritic-specific branched cationic peptide (DP). The system provides a non-toxic in-vitro method of delivering a polynucleotide to immune cells, including dendritic cells, comprising of contacting the cell in cell culture medium with a nanocarrier wherein the method is non-toxic to the cells. The methods described in the invention can be used for treating a subject in need of gene therapy, comprising administering to the subject an effective amount of the system comprising of a polynucleotide, wherein the polynucleotide contains a gen of interest for gene therapy.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
C08G 65/334 - Polymères modifiés par post-traitement chimique avec des composés organiques contenant du soufre
11.
TOPICAL DELIVERY OF LIPOPROTEIN-MIMETIC NANOPARTICLES
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
Provided herein are peptide amphiphiles (PAs), supramolecular assemblies comprising PAs, compositions comprising PAs, and methods of use thereof. In some embodiments, provided herein are supramolecular assemblies comprising an IKVAV PA and a growth factor mimetic PA. In some embodiments, the PAs, compositions, and supramolecular assemblies described herein are used in methods of treating nervous system injury.
Spherical nucleic acids (SNAs) are an attractive platform for therapeutic delivery due to their chemically tunable structures, biocompatibility, and ability to rapidly enter cells without transfection reagents. The present disclosure provides SNAs and strategies for delivering gene editing proteins into cells. The delivered gene editing proteins remain enzymatically active and rapidly enter mammalian cells.
The present disclosure pertains to the field of personalized medicine and methods for treating prostate cancer. In particular, the disclosure relates to the use of immune content scores to identify individuals in need of treatment for prostate cancer who are likely to be responsive to immunotherapy. The disclosure further relates to methods and immune content scores that identify tumors with enhanced immune activity and are prognostic for metastasis-free and disease-free survival for cancer patients.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
15.
DEVICES AND SYSTEMS FOR PREVENTING THE DEVELOPMENT OF PRESSURE ULCERS
A continuous bedside pressure monitoring (CBPM) device includes an array of pressure sensors, a controller including a processor and a memory, the controller operatively coupled to the array of pressure sensors, a communication interface operatively coupled to the controller, and a flexible housing enclosing the array of pressure sensors, the controller, and the communication interface.
The disclosure relates to methods, systems, kits and probe sets for the identification, determination, diagnosis, and/or prognosis of homologous recombination deficiency prostate cancer in a subject. The disclosure also provides biomarkers and clinically useful genomic classifiers for identifying homologous recombination deficiency prostate cancer, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing. The methods, systems, kits and probe sets can provide expression-based analysis of biomarkers for purposes of homologous recombination deficiency prostate cancer in a subject. Methods of treating homologous recombination deficiency prostate cancer based on expression analysis are also provided. The methods and classifiers of the present disclosure are also useful for predicting response to anticancer therapy (e.g., PARP inhibitors).
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p.ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
G16B 25/10 - Profilage de l’expression de gènes ou de protéines; Estimation ou normalisation de ratio d’expression
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
C40B 40/06 - Bibliothèques comprenant des nucléotides ou des polynucléotides ou leurs dérivés
17.
HYDROPHOBIC DRUGS IN ORGANIC CORE HIGH DENSITY LIPOPROTEIN (HDL) NANOPARTICLES
Disclosed herein are high-density lipoprotein-like nanoparticles (HDL-NP) having a soft material core (e.g., a lipid-conjugated inorganic core) associated with hydrophobic therapeutic agents. In some embodiments, the HDL-NPs are targeted to scavenger receptor type B1 (SR-B1). In some embodiments, the hydrophobic therapeutic agents are chemotherapeutic agents. Also disclosed herein are methods for treating disorders such as cancer with the HDL-NPs.
A61K 47/24 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p.ex. cyclométhicone ou phospholipides
A system for performing integrated mapping and electroporation includes a basket catheter that includes a plurality of splines and a plurality of electrodes mounted to each spline in the plurality of splines. The system also includes a controller device connected to the basket catheter. The controller device includes a processor configured to activate at least a subset of electrodes to perform electroporation, where activation of at least the subset of electrodes generates current paths between electrodes on a given spline and between electrodes on adjacent splines.
Provided are systems and methods for wireless, LCR-based, passive sensor systems for catheter or other implantable deployment using collapsible electromechanics. Each sensor system includes a deformable coil and a capacitive pressure sensor, collectively forming a LCR circuit having a self-resonant frequency. Multiple sensor systems may be implanted in a collapsible artificial valve to non-invasively detect the status of the collapsible artificial valve. Specifically, when the collapsible artificial valve is implanted in a mammal subject, antennas may be disposed on the skin of the mammal subject to wirelessly measure the self-resonant frequencies of the LCR circuits of the sensor systems. Thus, the blood pressure of the mammal subject may be calculated based on the self-resonant frequencies measured by the antenna, and the status of the collapsible artificial valve may be determined based on the blood pressure.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/02 - Mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin; Détermination combinée du pouls, du rythme cardiaque, de la pression sanguine; Evaluation d'un état cardio-vasculaire non prévue ailleurs, p.ex. utilisant la combinaison de techniques prévues dans le présent groupe et des techniques d'électrocardiographie; Sondes cardiaques pour mesurer la pression sanguine
The present invention provides methods of making anti-cancer compositions by activating 4-1BBL+ B cells using a CD40 agonist and ?F??. The anti-cancer compositions produced by these methods may be used as an immunotherapy for the treatment of cancer, either alone or in combination with radiation, chemotherapeutics and/or checkpoint blockade.
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
21.
ENGINEERED N-GLYCOSYLTRANSFERASES WITH ALTERED SPECIFICITIES
Disclosed are compositions, systems, and methods for synthesizing glycoproteins or recombinant glycoprotein protein in vitro and in vivo. In particular, the present invention relates to modified N-glycosyltransf erases (NGTs), method for generating modified NGTs, methods for identifying and/or generating modified acceptor peptide sequences for glycosylation by NGTs, and methods for preparing glycoproteins and recombinant glycoproteins in vitro and in vivo using the modified NGTs and/or acceptor peptide sequences.
Polypeptide inhibitors of SARS-CoV-2 are disclosed comprising an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-17, 19-21, 23-34 and 100-101, and their use for treating and limiting development of SARS-CoV-2 infection.
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
23.
COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT
A method of treating a cancer in a mammalian subject with a tumor signature characterized by any one or more of (i) a level of sirtuin (SIRT3) protein that is below a first predetermined threshold level, (ii) a level of manganese superoxide dismutase acetylated at the lysine 68 residue (AcK68) that exceeds a second predetermined threshold level, and (iii) expression levels of hypoxia-inducible factor 2a (HIF2a) that exceed a third predetermined threshold level indicative of lineage plasticity for stemness, the method comprising administering to the mammalian subject a therapeutically effective amount of a pentaaza macrocyclic ring complex corresponding to the Formula (I) below, optionally with administration of a further anti-cancer therapeutic agent.
The disclosure is generally related to nanoparticles have an oxidized tumor cell lysate encapsulated therein and oligonucleotides on the surface thereof. Methods of making and using the nanoparticles are also provided herein.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A method of forming a halide perovskite nanocrystal array having a plurality of halide perovskite nanocrystals arranged in a pattern can include coating an array of pens with a first ink comprising at least one first perovskite precursor having the formula AX and at least one second perovskite precursor having the formula BX'2 dissolved in a solvent. A is a cation, B is a metal, and X and X' are each a halogen. The method further includes contacting a substrate with the coated pen array to thereby deposit the first ink indias a pattern of printed indicia on the substrate. The printed indicia form nanoreactors on the substrate and a halide perovskite nanocrystal nucleates and grows within each nanoreactor to form the halide perovskite nanocrystal array.
C30B 7/00 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p.ex. à partir de solutions aqueuses
C30B 7/02 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p.ex. à partir de solutions aqueuses par évaporation du solvant
26.
METHOD OF ENHANCING AQUEOUS HUMOR OUTFLOW AND REDUCING INTRAOCULAR PRESSURE
The disclosure relates to methods of enhancing aqueous humor outflow via the conventional outflow tract in the eye in a subject in need thereof, or reducing intraocular pressure in a subject in need thereof.
CHIMERIC FUSIONS BETWEEN C4-BINDING PROTEIN C-TERMINAL SEGMENT AND ANGIOPOIETIN-1 FIBRINOGEN-LIKE DOMAIN AS ANGIOPOIETIN MIMETICS AND TIE2 AGONISTS TO TREAT VASCULAR DISEASES
C07K 14/435 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/22 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
28.
POTENT HUMAN NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS
Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating diseases and disorders associated with nNOS such as Alzheimer's, Parkinson's, and Huntington's diseases, and amytrophic lateral sclerosis, cerebral palsy, stroke/ischemic brain damage, and migraine headaches.
C07D 213/73 - Radicaux amino ou imino non substitués
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
C07D 213/74 - Radicaux amino ou imino substitués par des radicaux hydrocarbonés ou par des radicaux hydrocarbonés substitués
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
29.
METHOD OF PREPARING SILICONE-ACRYLATE HYBRID COMPOSITION AND HYBRID COMPOSITION FORMED THEREBY
A method of preparing a silicone-acrylate hybrid composition is provided. The method comprises irradiating an acrylate composition in the presence of: (i) a silicone article, and/or (ii) a silicone composition, to polymerize the acrylate composition and give the silicone-acrylate hybrid composition. The acrylate composition comprises an acrylate compound and an initiator, where the acrylate compound has the general formula (A):wherein each R is independently selected from H and substituted or unsubstituted hydrocarbyl groups, R1 is H or a substituted or unsubstituted hydrocarbyl group having from 1 to 10 carbon atoms, n is an integer equal to or greater than 1, and R2 is selected from R1, an amine group, an alkyl group, an alkyl group substituted with a hydroxyl group or an amino group, or a moiety having a valency of n greater than 1 to 4.
C08L 51/08 - Compositions contenant des polymères greffés dans lesquels le composant greffé est obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone; Compositions contenant des dérivés de tels polymères greffés sur des composés macromoléculaires obtenus autrement que par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
Provided herein are methods of producing lyophilized reagents with desired physical characteristics, and the lyophilized reagents produced thereby. In particular, lyophilized combinations of reagents are provided with specific physical geometries that provide optimized use in assays and devices.
F26B 5/06 - Procédés de séchage d'un matériau solide ou d'objets n'impliquant pas l'utilisation de chaleur par évaporation ou sublimation de l'humidité sous une pression réduite, p.ex. sous vide le procédé impliquant la congélation
31.
MODULAR, CELL-FREE PROTEIN EXPRESSION VECTORS TO ACCELERATE BIOLOGICAL DESIGN IN CELLS
Disclosed are compositions, methods, and kits for performing cell-free protein synthesis (CFPS) and for expressing proteins in cells. Particularly disclosed are vectors comprising Golden Gate sites for cloning, methods for preparing such vectors, and the use thereof for performing CFPS and for expressing proteins in cells such as in naturally occurring or recombinant species of Clostridia, including Clostridium autoethanogenum.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/67 - Méthodes générales pour favoriser l'expression
C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p.ex. Lactobacillus, Micromonospora
32.
INHIBITION OF THE VE-PTP PHOSPHATASE PROTECTS THE KIDNEY FROM ISCHEMIA-REPERFUSION INJURY
This disclosure relates to inhibition of the VE-PTP phosphatase to protect the kidney from ischemia-reperfusion injury. This disclosure also relates to conditional knockout of VE-PTP to protect or improve the renal function in ischemia-reperfusion injury. This disclosure identifies VE-PTP as a promising therapeutic target for renal protection in ischemia-reperfusion injury and proposes using small molecule VE-PTP inhibitor to bestow protection in the context of acute kidney injury.
Disclosed are protocols for preparing cell-free extracts preparation protocols that are enriched in membrane vesicles and use of the disclosed extract in cell-free glycoprotein synthesis methods and platforms for increasing glycoprotein yields.
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p.ex. glutathion
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p.ex. alpha-, bêta- ou gamma-cyclodextrines
Disclosed herein are compositions and methods for treating a subject having cancer and other ferroptosis disorders with high density lipoprotein-like nanoparticles that induce ferroptosis.
Described herein are Natural Killer Group 2D (NKG2D) agonist complexes comprising a soluble MHC I Chain-related molecule (sMIC) and a non-blocking sMIC- neutralizing antibody. Methods for activating CD8 T cells and methods for treating MIC- negative cancers and viral infections using such complexes are also provided.
Provided herein are materials, methods, and devices for the targeted delivery of agents. In particular, provided herein are materials, methods, and devices for the targeted delivery of agents to the atria or ventricles of the heart.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61M 37/00 - Autres appareils pour introduire des agents dans le corps; Percutanisation, c. à d. introduction de médicaments dans le corps par diffusion à travers la peau
38.
METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR
Methods of treating a disorder associated with elevated NMDAR antibodies in a patient in need thereof are provided comprising, for example, administering to the patient an effective amount of a spiro-ß-lactam compound.
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p.ex. cromakalim
A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p.ex. kétorolac, physostigmine
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
Disclosed herein are nanostructures, compositions, and methods for treating ocular disorders, injuries, and infections using RNA complexed nanoparticles (e.g., RNA-templated lipoprotein particles, miRNA-high density lipoprotein particles). These nanostructures are contemplated in topical therapies.
Systems, devices, and methods for dispensing a of fluidic sample to each of a plurality of targets are disclosed. An example apparatus for dispensing a fluidic sample includes an inlet port to input a sample material, and a first sample nozzle and a second sample nozzle fluidically coupled to the inlet port to expel the sample material, wherein a tubular junction fluidically couples the inlet port to a first tubular fluid path that terminates in the first sample nozzle and to a second tubular fluid path that terminates in the second sample nozzle, wherein a cross-sectional area of the tubular junction is less than an average cross-sectional area of the first tubular fluid path and the second tubular fluid path, and wherein the cross-sectional area of the tubular junction is selected to draw the sample material from the inlet port into the tubular junction via capillary action.
G01N 35/08 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant un courant d'échantillons discrets circulant dans une canalisation, p.ex. analyse à injection dans un écoulement
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p.ex. dispositifs d'aspiration, dispositifs d'injection
Methods and apparatus comprising a dewetting material and a polymerization liquid that are immiscible and dewetting, and can be used for the formation of three-dimensional objects, wherein the method does not require a dead zone. Additionally, methods and apparatus that employ the use of a flowing dewetting material to provide a shearing interface to reduce interfacial adhesive forces.
B29C 64/135 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux utilisant des couches de liquide à solidification sélective caractérisés par la source d'énergie à cet effet, p.ex. par irradiation globale combinée avec un masque la source d’énergie étant concentrée, p.ex. lasers à balayage ou sources lumineuses focalisées
One example includes a tunable current-mirror qubit. The qubit includes a plurality of flux tunable elements disposed in a circuit loop. A first portion of the flux tunable elements can be configured to receive a first input flux and a remaining portion of the flux tunable elements can be configured to receive a second input flux to control a mode of the tunable current-mirror qubit between a microwave excitation mode to facilitate excitation or quantum state manipulation of the tunable current-mirror qubit via a microwave input signal and a noise-protected mode to facilitate storage of the quantum state of the tunable current-mirror qubit. The qubit also includes at least one capacitor interconnecting nodes between respective pairs of the flux tunable elements to facilitate formation of Cooper-pair excitons in each of the microwave excitation mode and the noise-protected mode.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
43.
CELL-FREE PROTEIN SYNTHESIS PLATFORMS DERIVED FROM CLOSTRIDIA
Disclosed are compositions, methods, and kits for performing cell-free RNA transcription and/or cell-free protein synthesis (CFPS). The disclosed compositions, methods, and kits include or utilize components prepared from a species of Clostridia such as cellular extracts from Clostridium autoethanogenum.
Disclosed are components, systems, and methods for glycoprotein protein synthesis in vitro and in vivo. In particular, the disclosed components, systems, and methods relate to modular platforms for producing glycoproteins. The components, systems, and methods disclosed herein may be used in synthesizing glycoproteins and recombinant glycoproteins in cell-free protein synthesis (CFPS) and in modified cells.
Provided herein are compositions, methods, and devices for the treatment and prevention of atrial fibrillation (AF) using gene therapy techniques. In particular, oxidative stress (OS) and parasympathetic nervous system signaling are inhibited to prevent and/or reverse the electrical remodeling that underlies AF.
Disclosed herein are spherical high-density lipoprotein-like nanoparticles (HDL-NP) having a soft material core (e.g., a lipid-conjugated inorganic core). Also disclosed herein are methods for synthesizing the spherical HDL-NPs. Also disclosed herein are methods for treating disorders such as cardiovascular disease, cancer, inflammatory disorders or reducing NF-kB activity with the spherical HDL-NPs.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
Provided herein are methods for rapid detection of RNA in a sample. The methods comprise providing a reaction mixture containing the sample, amplification reagents, and a polymerase enzyme having both RNA and DNA-dependent polymerase activity; reverse transcribing the RNA to DNA by incubating for a reverse transcription time of no longer than 5 minutes; and amplifying the DNA by performing a thermal cycling protocol comprising a plurality of amplification cycles, wherein each amplification cycle comprises at least a denaturation step and an annealing step.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une transférase
48.
BIOCONJUGATE VACCINES SYNTHESIS IN PROKARYOTIC CELL LYSATES
Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins, which may be utilized in vaccines, including anti- bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. Suitable carriers may include but are not limited to Haemophilus influenzae protein D (PD), Neisseria meningitidis porin protein (PorA), Corynebacterium diphtheriae toxin (CRM 197), Clostridium tetani toxin (TT), and Escherichia coli maltose binding protein, and variants thereof.
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p.ex. glutathion
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p.ex. alpha-, bêta- ou gamma-cyclodextrines
49.
USE OF ANNEXINS IN PREVENTING AND TREATING MUSCLE MEMBRANE INJURY
The present disclosure provides compositions and methods for increasing the activity of an annexin protein and in one aspect provides an agent which is a protein having at least 90% sequence identity to annexin A6 as depicted in SEQ ID NO: 7 or SEQ ID NO: 8 or a combination thereof or a post-translationally modified form thereof, or a polynucleotide that encodes an extracellular protein having at least 90% sequence identity to annexin A6 as depicted in SEQ ID NO: 7 or SEQ ID NO: 8 or a combination thereof or a modified form thereof; to treat a cellular membrane injury, or delaying onset, enhancing recovery from cellular membrane injury, or preventing a cellular membrane injury, in a patient in need thereof.
Disclosed herein are methods and compositions for administering immunotherapy to a subject in need thereof and for treating a subject in need thereof, where in the methods the subject is administered an effective amount of an inhibitor of nNOS for inducing an immunotherapeutic response in the subject and for treating the subject. The disclosed methods and composition may be utilized for treating a subject having a cell proliferative disease or disorder such as melanoma.
The present disclosure is generally directed to methods for making protein polymers. The methods comprise utilizing oligonucleotides for controlling the association pathway of oligonucleotide-functionalized proteins into oligomeric/polymeric materials.
C07K 1/00 - Procédés généraux de préparation de peptides
A61K 38/14 - Peptides contenant des radicaux saccharide; Leurs dérivés
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques
52.
POLYELEMENTAL HETEROSTRUCTURE NANOPARTICLES AND METHODS OF MAKING THE SAME
Disclosed herein are method and design rules for making polyelemental systems with specific heterostructures, including tetra-phase nanopartides with as many as six junctions. In accordance with an embodiment, a method of making a tetra-phase polyelemental nanoparticle using tri-phase nanoparticle architectures can include selecting two or more triphase nanoparticle architectures, wherein the two or more tri-phase nanoparticle architectures are one or more striped tri-phase architectures, one or more pie-shaped tri-phase architectures, or combinations thereof; identifying from the selected two or more tri-phase nanoparticle architectures groups of metals for generating each of the two or more tri-phase nanoparticle architectures; contacting a tip coated with an ink to a substrate to form a nanoreactor, the ink comprising block copolymer and the metals from the groups of metals identified for generating each of the two or more tri-phase nanoparticle architectures; and annealing the nanoreactors under conditions sufficient to synthesize a tetra-phase polyelemental nanoparticle.
B22F 9/02 - Fabrication des poudres métalliques ou de leurs suspensions; Appareils ou dispositifs spécialement adaptés à cet effet par des procédés physiques
B82Y 40/00 - Fabrication ou traitement des nanostructures
B82Y 40/00 - Fabrication ou traitement des nanostructures
B01J 23/40 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe des métaux nobles des métaux du groupe du platine
B01J 23/46 - Ruthénium, rhodium, osmium ou iridium
B01J 23/70 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe du cuivre ou des métaux du groupe du fer
B22F 9/18 - Fabrication des poudres métalliques ou de leurs suspensions; Appareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique avec réduction de mélanges métalliques
54.
AUTOMATED SAMPLE DEPOSITION AND STAINING SYSTEMS AND ASSOCIATED METHODS
Cell deposition and staining apparatuses and methods are disclosed herein. In particular, the deposition and staining apparatuses disclosed herein provide low-volume, automated bench top systems for depositing and staining cellular samples on a cytological slide. An example deposition and staining apparatus includes a housing having an access door; a substrate processing holder located within the housing configured to hold one or more substrates and/or one or more substrate cartridges, wherein the substrate processing holder is accessible when the access door is in an open configuration; at least one opening located at least partially above at least a portion of the substrate processing holder; a spray nozzle configured to dispense a gaseous substance into the substrate processing area; a user interface configured receive an input from a user, and in response to receiving the input, cause execution of a pre-programmed protocol; and a waste and/or reagent holder element.
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p.ex. dispositifs d'aspiration, dispositifs d'injection
55.
PROCESS FOR THE SYNTHESIS OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID
Provided herein are processes, compounds and compositions for making (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid. Also provided herein a pharmaceutical composition containing (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid.
C07C 227/04 - Formation de groupes amino dans des composés contenant des groupes carboxyle
A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p.ex. sésamine
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p.ex. quinuclidine
C07C 227/12 - Formation de groupes amino et carboxyle
C07C 229/48 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino ou carboxyle liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et des groupes carboxyle liés à des atomes de carbone du même cycle non condensé
C07D 317/72 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant deux atomes d'oxygène comme uniques hétéro-atomes du cycle comportant les hétéro-atomes en positions 1, 3 condensés en spiro avec des carbocycles
56.
FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
UNIVERSITY OF KANSAS (USA)
NORTHWESTERN UNIVERSITY (USA)
Inventeur(s)
Rudloff, Udo
Kozlov, Serguei
Marugan, Juan Jose
Huang, Sui
Patnaik, Samarjit
Braisted, John C.
Southall, Noel T.
Ferrer, Marc
Dextras, Christopher
Haslam, John
Baltezor, Michael
Abrégé
Disclosed are pharmaceutical formulations comprising a compound of formula (I): in which R1, R2, R3, and R4 are as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods for treating pancreatic adenocarcinoma comprising administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and methods of detecting the change in expression levels of one or both of FoxA1 and FoxO6 in a pancreatic adenocarcinoma tumor sample from a mammal, wherein the mammal has been administered a compound of formula (I), or a pharmaceutically acceptable salt thereof.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliques; Leurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p.ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
This disclosure provides methods of detecting sub-acute rejection and other categories of rejection in kidney transplant recipients using unique sets of gene expression markers.
C12Q 1/6837 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide utilisant des réseaux de sondes ou des puces à sondes
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
Provided are conformable devices to measure subdermal fluid flow and related methods. A soft, stretchable and flexible substrate supports a thermal actuator and various specially positioned temperature sensors. A microprocessor in electronic communication with sensors calculates subdermal fluid flow from the measured upstream and downstream temperatures, as well as various application-dependent parameters. Devices and methods provided herein are particularly useful for measuring cerebral spinal fluid in a ventricular shunt placed for treatment of hydrocephalus.
Provided are conformable devices to measure subdermal fluid flow and related methods. A soft, stretchable and flexible substrate supports a thermal actuator and various specially positioned temperature sensors. A microprocessor in electronic communication with sensors calculates subdermal fluid flow from the measured upstream and downstream temperatures, as well as various application-dependent parameters. Devices and methods provided herein are particularly useful for measuring cerebral spinal fluid in a ventricular shunt placed for treatment of hydrocephalus.
The disclosure contains a method of quantifying and/or evaluating metal ions in a dentifrice, wherein the method comprises subjecting the dentifrice to X-ray absorption spectroscopy (XAS), and wherein the XAS is used to measure and/or evaluate the metal ions in the dentifrice. Also disclosed are methods of selecting and screening for dentifrices based upon the evaluation and quantification of their metal ion content.
G01N 23/087 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en transmettant la radiation à travers le matériau et mesurant l'absorption le rayonnement consistant en rayons X en utilisant des rayons X polyénergétiques
61.
WATER-SOLUBLE SALT PARTICLE CONTAINING COMPOSITIONS AND POROUS MATERIALS MADE THEREFROM
Compositions for forming porous materials and three-dimensional objects, including fibers, films and coatings made from the materials are provided. Also provided are methods for forming the porous objects from the compositions. The compositions include a solvent, a polymer binder that is soluble in the solvent, and solid particles that are insoluble in the solvent. The solid particles include water-soluble salt particles that can be selectively dissolved from objects made from the compositions to render the resulting structures porous.
C08J 9/12 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolaires; Leur post-traitement utilisant des gaz de gonflage produits par un agent de gonflage introduit au préalable par un agent physique de gonflage
A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
C08J 9/18 - Fabrication de particules expansibles par imprégnation des particules du polymère avec l'agent de gonflage
C08J 9/26 - Mise en œuvre de substances macromoléculaires pour produire des matériaux ou objets poreux ou alvéolaires; Leur post-traitement par élimination d'une phase solide d'un objet ou d'une composition macromoléculaire, p.ex. par lessivage
Described herein are RAS-targeted therapeutics comprising a recombinant molecule of formula: x-C-y-DTA-DTB, wherein x is a polypeptide or absent; C is a cargo polypeptide comprising Ras/Rap1 -specific endopeptidase (RRSP); y comprises a polypeptide, a linker, or is absent; DTA is a diphtheria toxin enzymatic fragment comprising SEQ ID No: 26; and DTB is a diphtheria toxin translocation fragment comprising SEQ ID No: 4, wherein the DTA is linked to the DTB by a disulphide linkage. Methods and uses for treatment of a disease or disorder caused by increased RAS activity in cells are disclosed. In some embodiments, the recombinant molecule results in surprisingly efficacious delivery of RRSP and/or reduction of RAS, e.g., to single-digit picomolar concentrations in vitro. The methods or uses may be for treatment of a cancer caused by increased RAS activity, e.g. caused by constitutively activating RAS mutations. The cancer may be pancreatic cancer.
A61K 47/66 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé l’agent de modification étant un système de pré-ciblage impliquant un peptide ou une protéine pour cibler des cellules spécifiques
The present disclosure generally relates to metal-organic framework nanoparticles containing terminal phosphate-modified oligonucleotides, methods for making the same, and methods of using the same.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
Provided herein are devices that facilitate the magnetic separation of an analyte from a sample, and methods of use thereof. In particular embodiments, devices and methods are provided for the trans-interfacial magnetic separation (TIMS) of analytes from a sample.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/549 - Support organique avec un antigène ou un anticorps emprisonnés dans le support
65.
DEVICES AND METHODS FOR RAPID SAMPLE PROCESSING AND ANALYSIS
Provided herein are devices and methods for the rapid processing and analysis of samples. In particular, a small-volume sample (e.g., nucleic acid sample) is exposed to (e.g., contacted with) different temperature zones within a device to process (e.g., amplify) and/or analyze (e.g., quantitate) the sample in an assay.
B82Y 40/00 - Fabrication ou traitement des nanostructures
B05D 3/12 - Traitement préalable des surfaces sur lesquelles des liquides ou d'autres matériaux fluides doivent être appliqués; Traitement ultérieur des revêtements appliqués, p.ex. traitement intermédiaire d'un revêtement déjà appliqué, pour préparer les applications ultérieures de liquides ou d'autres matériaux fluides par des moyens mécaniques
G03F 7/00 - Production par voie photomécanique, p.ex. photolithographique, de surfaces texturées, p.ex. surfaces imprimées; Matériaux à cet effet, p.ex. comportant des photoréserves; Appareillages spécialement adaptés à cet effet
Provided herein are injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release. In particular, PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases.
A61L 15/18 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p.ex. serviettes hygiéniques, tampons contenant des matériaux inorganiques
Nanostructures having an inorganic core and a lipid layer capable of binding a lecithinxholesterol acyltransferase (LCAT) activator such as an apolipoprotein are provided herein. Methods of using the nanostructures and related devices and compositions for assessing the risk of developing a disease or condition or treating the disease or condition are also provided.
G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol
C12Q 1/48 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une transférase
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
69.
METHOD FOR THE FABRICATION OF THREE-DIMENSIONAL OBJECTS AND APPARATUS FOR SAME
Methods and apparatus comprising a dewetting phase and a polymerization liquid that are immiscible, and can be used for the formation of three-dimensional objects, wherein the method does not require a dead zone. Additionally, methods and apparatus that employ an optically transparent cooling apparatus to mitigate heat generated during the fabrication process, and the use of a mobile phase to provide a shearing interface to reduce interfacial adhesive forces.
B29C 67/00 - Techniques de façonnage non couvertes par les groupes , ou
70.
DELIVERY OF NITRIC OXIDE-RELEASING PHOSPHOLIPIDS, LIPOSOMES, AND HIGH DENSITY LIPOPROTEIN-LIKE NANOPARTICLES (HDL NPS) BY DRUG ELUTING STENTS AND INTRA-ARTERIAL INJECTION
Nanostructures having a lipid layer which are useful for delivering nitric oxide are provided herein. Methods of treating disease using the nanostructures are also provided, including methods of treating vascular diseases, angiogenesis, ischemia- reperfusion, etc. Implantable devices coated with the nanostructures are also encompassed within the invention.
A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
A61K 47/24 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p.ex. cyclométhicone ou phospholipides
Nanostructures having a core and a shell such as a lipid layer and optionally a lipoprotein which are useful for delivering nitric oxide are provided herein. Methods of treating disease using the nanostructures are also provided, including methods of treating vascular diseases, angiogenesis, ischemia-reperfusion, etc.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
72.
PHARMACEUTICAL COMBINATION OF AN ATYPICAL ANTIPSYCHOTIC AND AN NMDA MODULATOR FOR THE TREATMENT OF SCHIZOPHRENIA,BIPOLAR DISORDER, COGNITIVE IMPAIRMENT AND MAJOR DEPRESSIVE DISORDER
This disclosure features combinations of NMDA modulators and atypical antipsychotics. The disclosure provides for example, methods of treating schizophrenia, bipolar disorder, and/or cognitive impairment disorder in a patient in need thereof, comprising administering e.g., rapastinel and an atypical antipsychotic.
A61K 31/135 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
(S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID, AND RELATED COMPOUNDS AS GABA AMINOTRANSFERASE INACTIVATORS FOR THE TREATMENT OF EPILEPSY, ADDICTION AND HEPATOCELLULAR CARCINOMA
C07C 229/48 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino ou carboxyle liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino et des groupes carboxyle liés à des atomes de carbone du même cycle non condensé
A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
74.
ANNULOPLASTY RING FOR RECEIVING A REPLACEMENT VALVE
An annuloplasty ring including elastic features that make the ring optimal for receiving a subsequent prosthetic valve via a "Valve In Ring Procedure." The elastic features provide a squeezing force on the native valve annulus that both ensures coaptation of the native valve leaflets and also prevents paravalvular leakage around a subsequently-placed prosthetic valve.
The invention is directed to one or more antisense polynucleotides and their use in pharmaceutical compositions in a strategy to induce exon skipping in the ?-sarcoglycan gene in patients suffering from Limb-Girdle Muscular Dystrophy-2C (LGMD2C) or in patients at risk of such a disease. The invention also provides methods of preventing or treating muscular dystrophy, e.g., LGMD2C, by exon skipping in the gamma sarcoglycan gene using antisense polynucleotides. Accordingly, in some aspects the invention provides an isolated antisense oligonucleotide, wherein the oligonucleotide specifically hybridizes to an exon target region of a ?-sarcoglycan RNA. In another aspect, the the invention provides a method of inducing exon-skipping of a gamma sarcoglycan RNA, comprising delivering an antisense oligonucleotide or a composition to a cell.
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
76.
AUTOMATED SPECIMEN DEPOSITION SYSTEMS AND ASSOCIATED METHODS
Systems and methods that enable automated spray deposition of biological specimens carried on microscope slides are described herein. Aspects of the technology are directed, for example, to automated specimen deposition systems and methods of generating high-quality, reproducible specimen-bearing microscope slides in automated processing systems.
B05D 5/00 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces pour obtenir des effets, finis ou des structures de surface particuliers
77.
THE SEQUENCE-SPECIFIC CELLULAR UPTAKE OF SPHERICAL NUCLEIC ACID NANOPARTICLE CONJUGATES
Spherical nucleic acids (SNAs), consisting of densely packed, highly oriented polynucleotide strands attached to the surface of nanoparticles, are able to overcome the typical challenges of nucleic acid delivery. The present disclosure demonstrates that G-rich SNAs exhibit several-fold higher uptake into cells relative to SNAs rich in other nucleotides. This disclosure provides an effective strategy to maximize the intracellular delivery of SNAs, which is applicable to other nanoparticle systems, thus establishing an important design consideration for nanoparticle -based intracellular delivery of therapeutics.
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/115 - Aptamères, c. à d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation
78.
ORNITHINE AMINOTRANSFERASE INHIBITION WITH GABA ANALOGUES FOR TREATMENT OF HEPATOCELLULAR CARCINOMA
A61K 31/196 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p.ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques
C07K 1/00 - Procédés généraux de préparation de peptides
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with subclinical acute rejection (subAR). These genes sets are useful for diagnosis, prognosis, monitoring of subAR.
C12Q 1/6837 - Couplage enzymatique ou biochimique d’acides nucléiques à une phase solide utilisant des réseaux de sondes ou des puces à sondes
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
81.
INK COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING AND METHODS OF FORMING OBJECTS USING THE INK COMPOSITIONS
3D printable ink compositions for forming objects, films and coatings are provided. Also provided are methods of printing the ink compositions and methods for making the ink compositions. The ink compositions include an elastic polymer binder and may have high loadings of solid particles.
Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA- specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA- targeted imaging in vivo. "Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
C07K 5/037 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminée; Leurs dérivés contenant au moins une liaison peptidique anormale la liaison anormale étant formée par la chaîne latérale d'un alpha-amino-acide, p.ex. gamma-Glu, epsilon-Lys, glutathion
83.
METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY
The present invention is directed to contrast agents of Formula (I): wherein: Z is tetrazole or CO2Q; Q is H or a protecting group; Xi and X2 are each independently NH or 0; a is an integer selected from the group consisting of 1, 2, 3 and 4; c is an integer selected from the group consisting of 0, 1, 2, 3 and 4; each Rl, R2 and R4 is independently H or C1-C4 alkyl; each R3 is independently H, C1-C6 alkyl or C2-C12 aryl; W is independently 0 or S; Y is -NH- and can be present or absent; L is a linker, wherein the linker is selected from the group consisting of: ; and wherein: m is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7 and 8; each R5 is independently H or ¨COOR6 wherein each R6 is independently H or a Ci-C6 alkyl; n is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12; p is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7 and 8; Ch is a chelating moiety that can comprise one or more metals or radiometals; or a pharmaceutically acceptable salt thereof, for PSMA-specific Ti-weighted MR imaging.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
Aluminum-zirconium and aluminum-zirconium-lanthanide superalloys are described that can be used in high temperature, high stress and a variety of other applications. The lanthanide is preferably holmium, erbium, thulium or ytterbium, most preferably erbium. Also, methods of making the aforementioned alloys are disclosed. The superalloys, which have commercially-suitable hardness at temperatures above about 220°C, include nanoscale A13Zr precipitates and optionally nanoscale A13Er precipitates and nanoscale A13(Zr,Er) precipitates that create a high-strength alloy capable of withstanding intense heat conditions. These nanoscale precipitates have a L12-structure in a-A1(f.c.c) matrix, an average diameter of less than about 20 nanometers ("nm"), preferably less than about 10 nm, and more preferably about 4-6 nm and a high number density, which for example, is larger than about 1021 m-3, of the nanoscale precipitates. The formation of the high number density of nanoscale precipitates is thought to be due to the addition of inoculant, such as a Group 3A, 4A, and 5A metal or metalloid. Additionally, methods for increasing the diffusivity of Zr in A1 are disclosed.
Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter- particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
Composite ion-exchange materials for use in an ion-exchange column are provided. Also provided are ion-exchange columns packed with the materials and methods for using the materials to remove metal ions from samples, such as waste water samples. The composite ion-exchange materials comprise a composite material comprising a metal chalcogenide and an alginate, wherein the composite material is mixed with a granular material.
The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, providing a substrate, contacting the substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated substrate, and contacting the trihydroxyphenyl-treated substrate with an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof.
A61L 27/00 - Matériaux pour prothèses ou pour revêtement de prothèses
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
Disclosed are components and methods for RNA-directed DNA cleavage and gene editing. The components include and the methods utilize a Cas9 protein from Neisseria and one or more RNA molecules in order to direct the Cas9 protein to bind to and optionally cleave or nick a target sequence.
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligature; Utilisation de linkers non fonctionnels ou d'adaptateurs, p.ex. linkers contenant la séquence pour une endonucléase de restriction
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
Methods for recovering gold from gold-bearing materials are provided. The methods rely upon on the self-assembly of KAuBr4 and a-cyclodextrin (a-CD) in aqueous solution to form a co- precipitate, a 1 :2 complex, KAuBr4(a-CD)2 ("aBr"), either alone or in an extended {[K(OH2)6][AuBr4]?(a- CD)2}n chain superstructure (FIG. 1). The co-precipitation of aBr is selective for gold, even in the presence of other metals, including other square- planar noble metals. The method enables one to isolate gold from gold-bearing materials from diverse sources, as further described.
The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
A61K 47/59 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes
C22F 1/043 - Modification de la structure physique des métaux ou alliages non ferreux par traitement thermique ou par travail à chaud ou à froid de l'aluminium ou de ses alliages d'alliages avec le silicium comme second constituant majeur
C22C 21/02 - Alliages à base d'aluminium avec le silicium comme second constituant majeur
C22F 1/04 - Modification de la structure physique des métaux ou alliages non ferreux par traitement thermique ou par travail à chaud ou à froid de l'aluminium ou de ses alliages
A medical device (10) includes a surgical needle (12) attached to a hollow tubular suture (14). The suture is constructed of macroporous hollow tubular wall (16) that facilitates and allows tissue integration into the suture core (18) subsequent to introduction to the body, thereby preventing suture pull-through and improving biocompatibility.
Nanostructures, compositions and methods for treating cancers and other conditions are provided. In some cases, the nanostructures and/or compositions may be used to treat cancers or other diseases or conditions at least in part by controlling cholesterol metabolism in cells. The nanostructures and compositions may be used, for example, to control cholesterol influx and/or efflux in cells. In some cases, the nanostructures or compositions may be used to kill the cells. Examples of cancer cells that may be affected by the nanostructures and compositions described herein include those having scavenger receptor type B-I (SR-B1), B-cell lymphoma cells, non-Hodgkin's lymphoma cells, melanoma cells and/or others. In some embodiments, the nanostructures may be mimics of natural high-density lipoprotein (HDL).
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
UNIVERSITY OF KANSAS (USA)
NORTHWESTERN UNIVERSITY (USA)
Inventeur(s)
Frankowski, Kevin
Patnaik, Samarjit
Huang, Sui
Marugan, Juan Jose
Norton, John
Schoenen, Frank J.
Southall, Noel
Titus, Steven
Zheng, Wei
Wang, Chen
Abrégé
The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
98.
NANOCONJUGATES ABLE TO CROSS THE BLOOD-BRAIN BARRIER
Polyvalent nanoconjugates address the critical challenges in therapeutic use. The single-entity, targeted therapeutic is able to cross the blood-brain barrier (BBB) and is thus effective in the treatment of central nervous system (CNS) disorders. Further, despite the tremendously high cellular uptake of nanoconjugates, they exhibit no toxicity in the cell types tested thus far. This property is critical for therapeutic agent delivery applications for reducing off-target effects.
A method of making a titanium oxide-containing coating composition comprises attaching an initiator to a pretreated titanium oxide to form an initiator/pretreated titanium oxide complex. The pretreated titanium oxide includes a plurality of pretreated titanium oxide particles which are titanium oxide particles that are pretreated with at least one metal oxide. The initiator/pretreated titanium oxide complex is contacted with a polymerizable unsaturated monomer such that a polymeric encapsulate forms on the initiator/pretreated titanium oxide particles to form polymeric encapsulated titanium oxide particles.
C09C 3/00 - Traitement, en général, de substances inorganiques, autres que des charges fibreuses, pour améliorer leurs propriétés de pigmentation ou de charge
C09D 151/10 - Compositions de revêtement à base de polymères greffés dans lesquels le composant greffé est obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone; Compositions de revêtement à base de dérivés de tels polymères greffés sur des substances inorganiques
Provided herein are compositions, devices, and systems comprising thermoresponsive, biodegradable elastomeric materials, and methods of use and manufacture thereof.
brevets
